Biotech research and therapeutics by Rigel Pharmaceuticals
Rigel Pharmaceuticals to unveil RET fusion-positive tumor findings at ESMO 2026
Rigel Pharmaceuticals announced plans for both oral and poster presentations at the ESMO Congress 2026, focusing on clinical data for pralsetinib. The presentations will cover pralsetinib’s ...
Rigel Pharmaceuticals partners with PDSA_ITP for ITP awareness campaign this month
Rigel Pharmaceuticals has initiated a new partnership with the Platelet Disorder Support Association (PDSA_ITP) to support ITP awareness throughout this month. The campaign is part of ...
VEPPANU commercialized as new treatment class, Rigel Pharmaceuticals reveals
Rigel Pharmaceuticals has announced the commercial availability of VEPPANU (vepdegestrant) in the U.S. This follows the FDA's May approval of vepdegestrant, making it the first approved therapy in ...
Rigel Pharmaceuticals posts Q2 2026 earnings and schedules results webcast
Rigel Pharmaceuticals released its financial results for the second quarter of 2026 today. The company will host a webcast at 4:30 PM ET to discuss the outcomes in more detail. Stakeholders can ...
Rigel Pharmaceuticals secures rights to develop and market VEPPANU under new agreement
Rigel Pharmaceuticals announced the completion of a global license agreement to develop, manufacture, and commercialize VEPPANU, also known as vepdegestrant. The agreement marks a significant ...
Rigel Pharmaceuticals CEO to deliver company overview at Jefferies Global Healthcare Conference June 3
Rigel Pharmaceuticals announced that CEO Raul Rodriguez will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 8:45am ET in New York. Investors and ...
Rigel Pharmaceuticals invites ASCO26 attendees to visit booth at major industry event
Rigel Pharmaceuticals announced its participation in the ASCO Annual Meeting, aiming to connect with oncology professionals and industry peers. The company encouraged attendees to visit their ...
Rigel Pharmaceuticals partner Kissei files NDA in Japan for olutasidenib to treat relapsed AML
Rigel Pharmaceuticals announced that its partner Kissei has submitted a New Drug Application (NDA) in Japan for olutasidenib, aimed at treating relapsed or refractory acute myeloid leukemia (AML) ...
Rigel Pharmaceuticals inks worldwide agreement to develop and commercialize VEPPANU
Rigel Pharmaceuticals has announced an exclusive global license agreement to develop, manufacture, and commercialize VEPPANU (vepdegestrant). The move positions Rigel Pharmaceuticals to further ...
Rigel Pharmaceuticals secures global rights to develop and commercialize VEPPANU
Rigel Pharmaceuticals today announced it has entered into an exclusive, global license agreement to develop, manufacture and commercialize VEPPANU, also known as vepdegestrant. The company plans ...
Q1 2026 results and business update set for May 5, Rigel Pharmaceuticals confirms
Rigel Pharmaceuticals will release its financial results for the first quarter of 2026 and provide a business update on May 5. Investors and analysts await insights into the company’s ...
